Iterum Therapeutics PLC (ITRM) Expected to Announce Earnings of -$1.96 Per Share

Wall Street brokerages forecast that Iterum Therapeutics PLC (NASDAQ:ITRM) will post ($1.96) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Iterum Therapeutics’ earnings. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 13th.

On average, analysts expect that Iterum Therapeutics will report full year earnings of ($11.29) per share for the current year. For the next financial year, analysts anticipate that the business will post earnings of ($5.52) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Iterum Therapeutics.

Iterum Therapeutics (NASDAQ:ITRM) last released its earnings results on Tuesday, August 14th. The company reported ($2.22) earnings per share for the quarter, missing the consensus estimate of ($1.44) by ($0.78). The business had revenue of $0.19 million during the quarter.

ITRM has been the subject of several recent research reports. Guggenheim initiated coverage on Iterum Therapeutics in a research note on Tuesday, June 19th. They issued a “buy” rating and a $21.00 price objective for the company. Needham & Company LLC initiated coverage on Iterum Therapeutics in a research note on Tuesday, June 19th. They issued a “buy” rating and a $20.00 price objective for the company. Royal Bank of Canada initiated coverage on Iterum Therapeutics in a research note on Tuesday, June 19th. They issued an “outperform” rating and a $24.00 price objective for the company. Finally, Leerink Swann initiated coverage on Iterum Therapeutics in a research note on Tuesday, June 19th. They issued an “outperform” rating and a $18.00 price objective for the company.

NASDAQ ITRM opened at $8.91 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.53 and a current ratio of 11.53. Iterum Therapeutics has a 1-year low of $8.09 and a 1-year high of $13.00.

Institutional investors and hedge funds have recently made changes to their positions in the company. Glen Harbor Capital Management LLC purchased a new position in shares of Iterum Therapeutics in the 2nd quarter valued at about $318,000. Dean Capital Investments Management LLC purchased a new position in shares of Iterum Therapeutics in the 2nd quarter valued at about $406,000. Tyers Asset Management LLC purchased a new position in shares of Iterum Therapeutics in the 2nd quarter valued at about $437,000. Flinton Capital Management LLC purchased a new position in shares of Iterum Therapeutics in the 2nd quarter valued at about $556,000. Finally, Neuburgh Advisers LLC purchased a new position in shares of Iterum Therapeutics in the 2nd quarter valued at about $675,000. Institutional investors and hedge funds own 47.63% of the company’s stock.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Recommended Story: Return on Investment (ROI)

Get a free copy of the Zacks research report on Iterum Therapeutics (ITRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply